7*24 Hotline：
Beijing Shuanglu Pharmaceutical Co., Ltd
In July 1998, the company changed its name to "Beijing Shuanglu Pharmaceutical Co., Ltd." in August 2000, the company was restructured into a joint stock company. In September 2004, "Shuanglu pharmaceutical" stock [2] (Code: 002038) was solemnly listed on Shenzhen Stock Exchange. The industry of China Securities Regulatory Commission: classified medicine and biological products.
Since its establishment, the company has always adhered to the corporate philosophy of "survival by quality and development by innovation". In the past 10 years, it has researched, developed and put on the market two national class I new drugs and eight national class II new drugs with independent intellectual property rights. At the same time, there are nearly 20 independent national class I and class II new drugs that are in different stages of research and development or application for production from laboratory to clinical trials. In the next two years, the company will put dozens of new products on the market one after another. Some research and development projects have won the first and second prizes of Beijing Municipal and national science and technology progress awards for many times.
In 1997, 2000 and 2002, the company applied as an independent enterprise for four times and was supported by the national "863" Program Fund. Two projects were supported by the national technological innovation fund. In October 1996, it was recognized as a high-tech enterprise by Beijing Science and Technology Commission. In 1999, it was listed as a key supporting enterprise in Beijing and a backbone enterprise in the field of biopharmaceuticals. In 2000, 2003 and 2004, all dosage forms of the company passed the China drug quality certification (GMP) of the State Drug Administration. In July 2000, it was approved by the Ministry of science and technology of the people's Republic of China and the Chinese Academy of Sciences as a high-tech enterprise Accreditation (double high accreditation). It is the industrialization base of four national "863" program achievements.
Due to the uncertainty of health care reform in 2009 and the fierce competition in the pharmaceutical industry, the market has doubts about whether Shuanglu pharmaceutical can maintain high growth. As a result, in the hot bull market in the first half of the year, the trend is weak, and Shuanglu pharmaceutical is ranked second among the top ten bear stocks in 2009 [3].
In addition to injection products, data show that Shuanglu pharmaceutical's compound coenzyme and other products have a good growth. The company's sales revenue growth in the first three quarters is close to 50%, and its main revenue is 640 million, exceeding the total revenue of 620 million last year.
The company is a joint stock limited company jointly established by four legal entities including Xinxiang Bailu Chemical Fiber Group Co., Ltd. and five natural persons including Xu Mingbo in June 2000. With the approval of China Securities Regulatory Commission, the company issued A-share to the public by way of offering and listed on Shenzhen Stock Exchange on September 9, 2004.
oil wellhead